Positive lung cancer screens frequently receive suboptimal follow-up
1. In this retrospective cohort study, most patients with a positive lung cancer screening result received guideline-concordant follow-up, though nearly ...
Tag: lung cancer
Age-Based Screening for Lung Cancer Surveillance in the US
1. Current US Preventive Services Task Force (USPSTF) screening criteria for lung cancer excludes many at-risk individuals and has poor ...
2 Minute Medicine Rewind November 24, 2025
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age 1. Incidence rates ...
AI scans detect pancreatic cancer years before clinical diagnosis
Key Points: 1. The algorithm flags pancreatic ductal adenocarcinoma up to three years early with an AUROC > 0.92. 2. It runs on standard, ...
Tumor-infiltrating clonal hematopoiesis is associated with NSCLC recurrence
1. In this retrospective cohort study, the presence of tumor-infiltrating clonal hematopoiesis (TI-CH) was associated with an increased risk of ...
#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
1. Median overall survival was 13.6 months in the tarlatamab group and 8.3 months in the chemotherapy group, with HR ...
#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer
1. In patients with previously treated metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), treatment with sacituzumab ...
Ivonescimab improves survival in advanced non-small cell lung cancer
1. Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the pembrolizumab group. 2. Grade ...
